(S)-10-Hydroxycamptothecin

Modify Date: 2025-08-22 19:30:38

(S)-10-Hydroxycamptothecin structure	Common Name	(S)-10-Hydroxycamptothecin
	CAS Number	19685-09-7	Molecular Weight	364.351
	Density	1.6±0.1 g/cm3	Boiling Point	820.7±65.0 °C at 760 mmHg
	Molecular Formula	C₂₀H₁₆N₂O₅	Melting Point	265-270°C
	MSDS	N/A	Flash Point	450.1±34.3 °C

Use of (S)-10-Hydroxycamptothecin

(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.IC50 value:Target:In vitro: In vitro, the 10-hydroxycamptothecin nanosuspensions released the encapsulated drug with nearly zero-order kinetics, and the accumulative release reached 90% within 72 hours. In vitro cytotoxicity assay showed that the 10-hydroxycamptothecin nanosuspensions had significantly enhanced cytotoxicity against HepG2 cells compared to the commercially available 10-hydroxycamptothecin injections [1].In vivo: The in vivo study with H22 tumor-bearing mice and intravenous injection of the drug showed that in contrast to the 10-hydroxycamptothecin injections, the 10-hydroxycamptothecin nanosuspensions exhibited significantly enhanced biodistribution, particularly in the lung (393.40-fold AUC0–24 h, liver (192.35-fold AUC0–24 h, spleen (141.67-fold AUC0–24 h and tumor (64.21-fold AUC0–24 h. The 10-hydroxycamptothecin nanosuspensions also showed improved antitumor therapeutic efficacy over the injections (89.83% vs. 30.56%) [1].

Name	10-Hydroxycamptothecin
Synonym	More Synonyms

Description	(S)-10-Hydroxycamptothecin is a clinical therapy agent against hepatoma.IC50 value:Target:In vitro: In vitro, the 10-hydroxycamptothecin nanosuspensions released the encapsulated drug with nearly zero-order kinetics, and the accumulative release reached 90% within 72 hours. In vitro cytotoxicity assay showed that the 10-hydroxycamptothecin nanosuspensions had significantly enhanced cytotoxicity against HepG2 cells compared to the commercially available 10-hydroxycamptothecin injections [1].In vivo: The in vivo study with H22 tumor-bearing mice and intravenous injection of the drug showed that in contrast to the 10-hydroxycamptothecin injections, the 10-hydroxycamptothecin nanosuspensions exhibited significantly enhanced biodistribution, particularly in the lung (393.40-fold AUC0–24 h, liver (192.35-fold AUC0–24 h, spleen (141.67-fold AUC0–24 h and tumor (64.21-fold AUC0–24 h. The 10-hydroxycamptothecin nanosuspensions also showed improved antitumor therapeutic efficacy over the injections (89.83% vs. 30.56%) [1].
Related Catalog	Signaling Pathways >> Others >> Others Natural Products >> Alkaloid Research Areas >> Cancer
References	[1]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting. [2]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8

Description

Related Catalog

Signaling Pathways >> Others >> Others

Natural Products >> Alkaloid

Research Areas >> Cancer

References

[1]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance . Journal of Drug Targeting.

[2]. Min Liu, et al. Intracellular delivery of 10-hydroxycamptothecin with targeted nanostructured lipid carriers against multidrug resistance. J Drug Target, Early Online: 1–8

Density	1.6±0.1 g/cm3
Boiling Point	820.7±65.0 °C at 760 mmHg
Melting Point	265-270°C
Molecular Formula	C₂₀H₁₆N₂O₅
Molecular Weight	364.351
Flash Point	450.1±34.3 °C
Exact Mass	364.105927
PSA	101.65000
LogP	1.32
Vapour Pressure	0.0±3.1 mmHg at 25°C
Index of Refraction	1.777
InChIKey	HAWSQZCWOQZXHI-FQEVSTJZSA-N
SMILES	CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(O)ccc3nc2-1
Storage condition	-20°C Freezer

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UQ0491700

CAS REGISTRY NUMBER :: 19685-09-7

LAST UPDATED :: 198305

DATA ITEMS CITED :: 4

MOLECULAR FORMULA :: C20-H16-N2-O5.H2-O

MOLECULAR WEIGHT :: 382.40

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 104 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :: Sister chromatid exchange

TEST SYSTEM :: Human Cells - not otherwise specified

DOSE/DURATION :: 100 ug/L

REFERENCE :: YHHPAL Yaoxue Xuebao. Acta Pharmaceutica Sinica. Pharmaceutical Journal. (China International Book Trading Corp., POB 2820, Beijing, Peop. Rep. China) V.1- 1953- Suspended 1966-78. Volume(issue)/page/year: 21,492,1986

RIDADR	NONH for all modes of transport
HS Code	2934999090

Precursor 7
CAS#:7689-03-4 Campathecin CAS#:19685-10-0 (4S)-4-Ethyl-4-... CAS#:870527-52-9 1,2,6,7-tetrahy... CAS#:123948-88-9 (S)-10-((Dimeth...
CAS#:173442-34-7 (S)-4-ethyl-4-h... CAS#:86639-48-7 Camptothecin N-oxide CAS#:623-51-8 Ethylsulfanylacetat
DownStream 7
CAS#:91421-42-0 rubitecan CAS#:91421-43-1 9-Aminocamptothecin CAS#:86639-52-3 7-Ethyl-10-hydr... CAS#:19685-10-0 (4S)-4-Ethyl-4-...
CAS#:104267-73-4 9-Nitro-10-hydr... CAS#:123948-87-8 Topotecan hydro... CAS#:119413-54-6 Topotecan hydro...